ARL6 and prostate adenocarcinoma: In contrast, the mRNA expression of ARL-6 was markedly lower in UCEC (uterine corpus endometrial carcinoma), THCA (thyroid carcinoma), SKCM (Skin Cutaneous Melanoma), READ (Rectum adenocarcinoma), PRAD (prostate adenocarcinoma), LUSC (lung squamous cell carcinoma), LUAD (lung adenocarcinoma), KIRP (kidney renal papillary carcinoma), KIRC (kidney renal clear cell carcinoma), BRCA (breast invasive carcinoma), and BLCA (bladder urothelial carcinoma) (Figure 1A).